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Self-interactionPARK2, an ubiquitin ligase closely correlated with Parkinson's disease and cancer, has been shown to accu-
mulate at centrosomes to ubiquitinate misfolded proteins accumulated during interphase. In the present
study, we demonstrated that PARK2 can also localize to centrosomes in mitosis and that the protein does
not ﬂuctuate through the S- to M-phase. A C-terminal truncation of PARK2 resulted in a spindle assembly
checkpoint defect, characterized by HeLa cells able to bypass mitotic arrest induced by nocodazole and
form multinucleated cells when overexpressing the C-terminal truncated PARK2 protein. The spindle assem-
bly checkpoint defect may be due to a change in a biochemical or structural property of PARK2 caused by the
C-terminal truncation, resulting in a loss of self-interaction between PARK2 proteins.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
PARK2 protein, an E3 ligase associated with E2 ubiquitin conjugat-
ing enzymes such as UbcH7, promotes ubiquitination of several pro-
teins such as Cyclin E, CDCrel, and Synphilin-1, which are
subsequently targeted for degradation by proteasomes [1–4]. PARK2
consists of an ubiquitin-like domain (UBL) at its N-terminus and
two RING ﬁnger motifs ﬂanked by a cystein rich IBR motif (In-Be-
tween RING ﬁngers) at its C-terminus.
The sites of knownmutations in PARK2 span all regions of the pro-
tein including the UBL, linker, and RING-IBR-RING domains. Germline
mutation of PARK2 was reported as the cause of familial autosomal
recessive juvenile Parkinsonism (AR-JP), which is a common neuro-
degenerative disease characterized by the loss of dopaminergiccine, Mackay Medical College,
i City 252, Taiwan. Tel.: +886
iology, Immunology, and Bio-
Sec. 3, Hualien 970, Taiwan.
24.
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rights reserved.neurons in substantia nigra, resulting in postural imbalance, rigidity,
tremor, and bradykinesia [5]. PARK2 mutations compromise the abil-
ity of the protein to ubiquitinate cyclin E, which leads to aberrant mi-
tosis in cancer due to a decreased E3 ligase activity [6], suggesting
that PARK2 may play a role in cell cycle regulation and tumorigenesis
[7].
Recently, it has been shown that PARK2 can localize to microtu-
bules and stabilize its own structure through strong binding mediated
independently by the linkers, RING1, and RING2 domains [41]. The lo-
calization of PARK2 to microtubules is an important factor for its ubi-
quitin ligase activity toward misfolded substrates. PARK2 in SH-SY5Y
and HEK293 cells could be recruited to centrosomes by treatment
with the proteasome inhibitor lactacystin [8,9]. Furthermore, knock-
down of the PARK2 gene resulted in aberrant mitosis and formation
of micronuclei [6], suggesting that PARK2 plays a role in mitosis.
However, it is still unclear how PARK2 mutations promote tumori-
genesis, and whether PARK2 mutations affect mitosis progression.
In this study, we investigated the role of PARK2 in mitosis. Our re-
sults demonstrate that PARK2 can also be recruited to the centro-
somes in mitosis. The protein level of PARK2 did not ﬂuctuate
through S- to M-phase as compared to Securin. Furthermore, the C-
terminal truncation of PARK2, lacking part of the C-terminal RING2
domain, failed to interact with endogenous PARK2 proteins, but still
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overexpression of this C-terminal truncated PARK2 protein could se-
verely abrogate the normal function of the spindle assembly check-
point (SAC). It is known that any defect in the SAC may lead to
aneuploidy, a phenotype frequently observed in many tumor cells
and associated with tumorigenesis. Therefore, these ﬁndings suggest
a correlation of PARK2 with mitosis progression and tumorigenesis.
2. Materials and methods
2.1. Constructions and antibody
Wild-type PARK2 DNA fragment was PCR-ampliﬁed using the
primers 5′-gaattcaatgatagtgtttgtcaggttc-3′ and 5′-ggatccctacacgtcgaac-
cagtggt-3′. Similarly, PARK2ΔC12, with a deletion of the C-terminal 12
amino acids of PARK2, and PARK2ΔC40, lacking the C-terminal 40
amino acids of PARK2, DNA fragments were PCR-ampliﬁed using the
primers 5′-gaattcaatgatagtgtttgtcaggttc-3′ and 5′-gcggatccctaccactcg-
cagccacag-3′ and 5′-gaattcaatgatagtgtttgtcaggttc-3′ and 5′-gcggatcccta-
cactggtacatggcagcg-3′, respectively. The ampliﬁed DNA fragmentswere
then cloned into yT&A vector (yT&A Co., Taiwan). Vectors with inserts
were digested with restriction enzymes EcoRI and BamHI and sub-
cloned into the pEGFP-C1 vector (containing enhanced green ﬂuores-
cence protein of Aequorea victoria, Invitrogen) to obtain the EGFP-
PARK2, EGFP-PARK2ΔC12, and EGFP-PARK2ΔC40 constructs. Full
length PARK2 is also subcloned into pCMV-HA Vector (Clontech).
2.2. Cell culture, transfection, and cell synchronization
HeLa cells were cultivated following standard procedures. Cell
transfection was performed using Lipofetamine 2000 (Invitrogen) as
described in manufacture's manual. To synchronize cells, Hela cells
were treated with a double thymidine (DT; 2 mM thymidine) block.
To determine mitotic index or arrest cells in M phase, HeLa cells
were treated with 50 ng/ml nocodazole for 18 h. To inhibit protein
synthesis, Hela cells were treated with 1 mg/ml cyclohexamide
(Sigma) at various time points.
2.3. Western blot and co-immunoprecipitation
Rabbit anti-PARK2 polyclonal antibody (ab15954) is from Abcam
Co. Securin, EGFP,γ-tubulin, phosphohistone 3, cyclin A2, and α-
actin were detected with their speciﬁc antibodies (rabbit anti-
securin polyclonal antibody from Zymed Co, Cat No. 34-1500;
mouse anti-EGFP monoclonal antibody, clone GSN24, from Sigma
Co.; chicken anti-EGFP polyclonal antibody from Abcam Co., Cat No.
ab13970; rabbit anti-phosphohistone 3 from Millipore Co., Cat No.
06-570; rabbit anti-cyclinA2 polyclonal antibody from GeneTex Co.,
Cat No. GTX103042,; mouse anti-γ-tubulin monoclonal antibody,
clone GTU-88, from Sigma Co.; goat anti-α-actin from Santa Cruz
Co., Cat No. sc1616; mouse anti-HA monoclonal antibody, clone F-7,
from Santa Cruz Co.), and visualized by chemiluminescence (Dupont,
USA) after treating with HRP-conjugated secondary antibodies. An
immunoprecipitation assay was also performed in RIPA buffer
(25 mM Tris–HCl, pH 7.6, 150 mM NaCl, 1% NP40, 0.1% SDS) contain-
ing protease inhibitors and phosphatase inhibitors using rabbit anti-
GFP and protein A beads. The precipitated proteins from cell lysates
were analyzed as described above. To perform immunoblot analysis,
cells were lysed with RIPA buffer, 60 μg of each cell lysate was re-
solved by 10% SDS-PAGE and transferred to the PVDF membrane.
2.4. Immunoﬂuorescence microscopy
Immunoﬂuorescence staining simultaneously for PARK2 and γ-
tubulin was performed as follows: cells were rinsed twice with PBS,
ﬁxed by cold methanol, and then blocked with ﬁltered PBS containing1% skim milk. Puriﬁed rabbit anti-PARK2 antibody and mouse mono-
clonal anti-γ-tubulin were diluted 1/100 and 1/400, respectively, in
ﬁltered PBS buffer with 1% skim milk. FITC and Cy3-conjugated sec-
ondary antibodies were diluted 1/50 and 1/500, respectively, in ﬁl-
tered PBS with 1% skim milk. All antibody incubations were carried
out for 1 h at room temperature, followed by three washes with PBS
buffer. All stained cells were visualized using either an E800 ﬂuores-
cence microscope (Nikon Co.) or a confocal laser microscope (Leica
TCS SP5 AOBS). Red and green ﬂuorescent signals were merged by
computer software provided by Leica.
2.5. Detergent solubility assay
A detailed protein detergent solubility assay was described else-
where [10]. The transfected cells were lysed in detergent buffer
(0.5% Triton X-100 in PBS) and then centrifuged at 13,000 rpm for
15 min at 4 °C after incubation for 20 min on ice. Supernatant and
pellet fractions were separated and the pellet fraction was washed
once with detergent buffer and resuspended in SDS-containing
Laemmli sample buffer in a volume equal to the supernatant. Equal
amounts of detergent-soluble and pellet fractions were supplemen-
ted with the same volume sample buffer or detergent buffer. Protein
level was analyzed by Western blotting after boiling for 10 min.
2.6. Puriﬁcation of PARK2 and PARK2CΔ40
The PARK2 and PARK2CΔ40 was PCR-ampliﬁed and cloned into
pET-28a vector (Novagen). The constructed plasmid was transformed
into Escherichia coli M15. To induce overexpression of PARK2 and
PARK2ΔC40, the transformants were incubated at 37 °C until an
O.D.600nm of 0.5 before the addition of 1 mM IPTG. For protein puriﬁ-
cation, the collected pellet was resuspended in 50 mM phosphate
buffer, pH 7.0. The supernatant was ﬁrst puriﬁed using Ni-NTA col-
umn (GE). The eluates containing PARK2 proteins were pooled and
further puriﬁed by FPLC system with Superdex-75 column (GE). The
puriﬁed proteins were lyophilized and stored at 4 °C.
2.7. Circular dichroism spectroscopy and secondary structure analyses
For circular dichroism (CD) measurements, a ﬁnal concentration
of 50 μM for both PARK2 and PARK2ΔC40 in 10 mM phosphate buffer,
pH 7.0, was used. CD spectra were recorded using a Synchrotron Cir-
cular Dichroism (SRCD) spectropolarimeter (BL04B beamline)
equipped with a thermal circulator accessory in the National Syn-
chrotron Radiation Research Center (NSRRC), Taiwan. All measure-
ments were performed in CaF2 cells with a path length of 0.075 cm.
Data were collected at wavelengths from 190 to 260 nm with a band-
width of 0.6 nm, and an averaging time of 1 s. At the beamline, the
linearity of HT signal was measured to determine the low wavelength
data cut-off limit. Every CD spectrum is reported as the average from
at least three individual samples. The reported CD spectra were cor-
rected for baseline using the phosphate buffer, pH 7.0. All measure-
ments were carried out at 25.0±0.2 °C. Secondary structure
analysis was performed in an online web server: Dichroweb (1, 2,
3) using CDSSTR program.
3. Results
3.1. Localization of PARK2 proteins in mitosis
Previously, PARK2 overexpressed in SH-SY5Y or HEK293 cells was
shown to be recruited to the centrosome during interphase [8,9].
Therefore, to examine the role of PARK2 in mitosis, we ﬁrst deter-
mined whether endogenous PARK2 also localized to centrosomes in
mitosis. PARK2 and γ-tubulin, a component of the centrosome, were
stained and visualized using confocal microscopy. Results showed
Fig. 1. Subcellular localization of endogenous PARK2. The ﬁxed cells were simulta-
neously stained with rabbit anti-PARK2 (see the assay for its speciﬁcity in supplemen-
tal Fig. S1) and mouse anti-γ-tubulin antibodies followed by Cy3-conjugated anti-
mouse IgG and FITC-conjugated anti-rabbit IgG antibodies. Chromosomal DNA was
stained with DAPI. Stained cells were visualized by confocal laser microscope. The γ-
tubulin indicates the location corresponding to the spindle poles.
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from prophase to anaphase, suggesting that PARK2 is also a
centrosome-associated protein in mitosis (Fig. 1).
3.2. PARK2 protein does not ﬂuctuate through cell cycle
Mutations in PARK2 may abrogate its ligase activity; compromis-
ing its ability to ubiquitinate cyclin E in cancer cells [6]. Because the
regulation of cyclin E protein is a cell cycle-dependent event, we in-
vestigated whether the level of PARK2 protein was also regulated in
different phases of the cell cycle. The level of PARK2 in S- and M-
phase cells was analyzed by Western blotting. As shown in Fig. 2a,
the expression of PARK2 protein did not ﬂuctuate from S- to M-
phase whereas the protein level of Securin was increased from S to
M phases.Fig. 2. Protein levels of PARK2 during cell cycle progression. (a) Cells were treated with a do
(noc; 50 ng/ml) to arrest in M phase. Asynchronous cell lysates (Asn) were used as a compa
dium to release cells from S phase arrest. Cells were collected at indicated times.The protein level of PARK2 and Securin was further veriﬁed in an
S-phase arrest/release experiment. Fig. 2b shows that the level of
PARK2 was maintained at a constant level from 0 to 14.5 h after re-
lease from a thymidine-induced S-phase block. However, consistent
with previous work [11], the protein level of Securin was greatly in-
creased from S to M-phase (Fig. 2b). Our result demonstrates that
the protein level of PARK2 does not ﬂuctuate throughout the cell
cycle.
3.3. Overexpression of PARK2ΔC12 and PARK2ΔC40 can bypass the mi-
totic arrest induced by nocodazole
It is well-known that when cells are defective in the SAC, cells will
bypass the mitotic arrest induced by the microtubule destabilizer
nocodazole, complete mitosis, and enter the next round of cell cycle
[13,16–21]. Previous studies have shown that the γ-TuRC complex
and Dido3 have a role in spindle assembly checkpoint in prometa-
phase, and that the disruption of these proteins may cause a defect
in SAC [12,13]. Since PARK2 also localized to the centrosome in mito-
sis (Fig. 1), and may bind to RanBP2/NUP358 [14], a kinetochore pro-
tein required for recruitment of the spindle checkpoint protein MAD1
to kinetochores [15], we wished to see whether PARK2 also had a
function in the SAC. To address this question, both PARK2ΔC12, a
PARK2 mutant protein bearing a Trp453Stop mutation, and
PARK2ΔC40, containing a deletion of the C-terminal 40 amino acids,
were fused to the C-terminus of EGFP (Enhanced Green Fluorescent
Protein of Aequorea victoria) to determine whether PARK2ΔC12 and
PARK2ΔC40 could cause a defect in SAC when overexpressed
(Fig. 3a and supplemental Fig. S2). If this were the case, ectopic ex-
pression of mutated PARK2 protein should cause cells to bypass the
mitotic arrest induced by the microtubule destabilizer nocodazole
and therefore enter G1 of the next round of cell cycle. After 18 h of
nocodazole treatment, 0.7% of cells expressing EGFP-PARK2ΔC12
and 0.8% of cells expressing EGFP-PARK2CΔ40 were in mitosis where-
as 48.3% of cells expressing EGFP and 46.3% of cells expressing EGFP-
PARK2 remained in the mitotic phase (Fig. 3b). Notably, as compared
to EGFP and EGFP-PARK2, ectopic over-expression of EGFP-
PARK2ΔC12 and EGFP-PARK2CΔ40 could result in severe lethality
(Fig. 3b), implying that ectopic expression of EGFP-PARK2ΔC12 and
EGFP-PARK2ΔC40 could result in a defect in the SAC. As shown inuble thymidine (DT; thymidine, 2 mM) block to arrest in S phase, and with nocodazole
rison. (b) Cells were treated with a double thymidine block and replaced by fresh me-
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Fig. 4. (a) Cells transfected with EGFP-PARK2ΔC40 for 48 h were ﬁxed and stained with DAPI and visualized using a confocal laser microscope.(b) Five hundred EGFP-PARK2, EGFP-
PARK2ΔC40, or EGFP-PARK2ΔC12-expressing cells were ﬁxed and counted as in (a) and repeated for three independent experiments. The statistical p value was obtained by the
STUDENT t-test.
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nent effect on the SAC, EGFP-PARK2ΔC40 was used for further
analysis.
It is possible that PARK2ΔC12 and PARK2ΔC40 prevented entry
into mitosis, which resulted in a lower accumulation of mitotic cells
after nocodazole treatment. To verify this possibility, we determined
whether EGFP-PARK2ΔC40 affected cell cycle progression. Cells
were synchronized in early S phase and then released into fresh
nocodazole-containing medium and collected for Western blotting
analysis at the indicated times after release from S phase arrest. As
compared to EGFP and EGFP-PARK2, ectopic expression of
PARK2ΔC40 did not cause a difference in the timing of appearance
and decline of the cell cycle regulated proteins cyclinA2, a S-M
phase marker, and phospho-Histone 3, an M phase marker (Fig. 3c).
This indicated that ectopic expression of PARK2ΔC40 did not alter
cell cycle progression from late G1 to mitosis.
Because subcellular localization is also important for proper pro-
tein function, we determined whether EGFP-PARK2ΔC40 localized
to centrosomes in M phase. Similar to EGFP-PARK2, EGFP-
PARK2ΔC40 also localized to the centrosome at prometaphase, sug-
gesting that the 40C-terminal amino acids were not a determinant
for this recruitment (Fig. 3d). We further determined whether GFP-
PARK2ΔC40 affected localization of wild type PARK2 to the centro-
somes in prometaphase. Both HA-tagged wild type PARK2 (HA-
PARK2) and EGFP-PARK2ΔC40 were cotransfected into cells for
immunoﬂuorescence microscopic analysis. We found that both HA-
PARK2 and EGFP-PARK2ΔC40 could co-localize to the centrosomes
(Supplemental Fig. S3), indicating that EGFP-PARK2ΔC40 did not in-
terfere with the ability of HA-PARK2 to localize to the centrosomes.3.4. Ectopic expression of PARK2ΔC40 induces an accumulation of
multinucleated cells
The formation of multinuclei is another frequently observed phe-
nomenon in SAC-defective cells [13,22–26]. Therefore, we investigat-
ed whether ectopic expression of EGFP-PARK2ΔC40 could also result
in the accumulation of multinucleated cells. As shown in Fig. 4a, ec-
topic expression of EGFP-PARK2ΔC40 resulted in mutlinucleation. At
48 h after transfection, ~5% of cells expressing EGFP and ~7% of cells
expressing EGFP-PARK2 showed multinucleation whereas 12.7% of
cells expressing EGFP-PARK2ΔC40 were multinucleated (Fig. 4b).
Therefore, as compared to EGFP and EGFP-PARK2, ectopic expressionFig. 3. (a) Schematic structure of PARK2 and PARK2 C-terminal deletions.(b) Ectopic express
(−) nocodazole (noc, 50 ng/ml) at 24 h after cells were transfected with EGFP, EGFP-PARK2
ment with nocodazole for 18 h. Two hundred cells were scored for each of three independe
three independent experiments. The statistical p value was obtained by the STUDENT t-test
with double thymidine and analyzed byWestern blot at 0, 3, 6, 9, 12 and 15 h as in Fig. 2.(d)
PARK2 and EGFP-PARK2ΔC40 localized to the spindle poles. Cells were ﬁxed and then simul
with FITC-conjugated anti-chicken IgG and Cy3-conjugated anti-mouse IgG antibodies.of EGFP-PARK2ΔC40 could result in an accumulation of multinu-
cleated cells.
3.5. Biochemical characterization of PARK2ΔC40
Although the C-terminal truncation of PARK2 resulted in a SAC de-
fect, the possible reason for this is still unclear. A change in the bio-
chemical properties of PARK2ΔC40 may be one possibility. To
further characterize the biochemical property of PARK2ΔC40, we per-
formed a detergent solubility assay [10]. EGFP-PARK2 proteins were
predominantly present in the detergent-soluble fraction when cells
were lysed with Triton-X 100 buffer (Fig. 5a). In contrast, a signiﬁcant
amount of EGFP-PARK2ΔC40 proteins were detected in the insoluble
pellet fraction similar to the mutant protein, PARK2W453X [27], indi-
cating a decreased solubility of EGFP-PARK2ΔC40.
The decrease in PARK2ΔC40 solubility could have been caused by
an alteration in protein stability. Therefore, we further examined pro-
tein stability for both EGFP-PARK2 and EGFP-PARK2ΔC40 in vivo.
After cyclohexamide treatment to inhibit translation, the levels of
both soluble EGFP-PARK2 and endogenous PARK2 proteins remained
constant whereas the level of soluble EGFP-PARK2ΔC40 proteins
gradually decreased (Fig. 5b and supplemental Fig. S4). Since the pro-
tein level of aggregated EGFP-PARK2ΔC40 proteins did not change in
the pellet after cycloheximide treatment (Fig. S4), the decrease in the
level of soluble EGFP-PARK2ΔC40 proteins should be not due to an in-
crease in the level of aggregated EGFP-PARK2ΔC40 proteins in the
pellet. This indicated that PARK2ΔC40 was less stable than wild
type PARK2. In addition, we performed co-immunoprecipitation
assays and discovered that, unlike wild type PARK2, PARK2ΔC40
failed to interact with endogenous PARK2 proteins in HeLa cells
(Fig. 5c), suggesting that truncation of the C-terminus of PARK2
resulted in changes to the biochemical properties of the protein.
3.6. Deletion of the C-terminal 40 amino acids results in a conformational
change of PARK2
As shown in the previous section, deletion of the C-terminal 40
amino acids affects the stability of PARK2 protein (Figs. 5b and S3).
We wonder if the decreased stability, solubility and loss of self-
interaction of PARK2ΔC40 are due to the conformational change.
Therefore, to investigate their structural property, both PARK2 and
PARK2ΔC40 proteins were expressed in, and puriﬁed from E. coli cells.ion of PARK2 and PARK2ΔC40 on the SAC. Hela cells were treated with (+) or without
, EGFP-PARK2ΔC40, or EGFP-PARK2ΔC12. Cells were collected for analyses after treat-
nt experiments. Each bar with standard deviation represents the average values from
.(c) HeLa cells transfected with EGFP, EGFP-PARK2, or EGFP-PARK2ΔC40 were treated
EGFP-PARK2ΔC40 did not alter its localization to the centrosome during mitosis. EGFP-
taneously stained with chicken anti-GFP and mouse anti-γ-tubulin antibodies followed
Fig. 5. Characterization of EGFP-PARK2 and EGFP-PARK2ΔC40(a) Hela cells were transfected with EGFP-PARK2 and EGFP-PARK2ΔC40 for 48 h. After lysis with Triton X-100 con-
taining buffer, both supernatants and pellets were analyzed by Western blot.(b) EGFP-PARK2 and EGFP-PARK2ΔC40-transfected cells were treated with cyclohexamide at the in-
dicated times. Proteins were extracted by RIPA buffer and detected byWestern blot.(c) Hela cells were transfected with EGFP-PARK2 and EGFP-PARK2ΔC40 for 48 h. Cells were then
lysed to perform co-immunoprecipitation using anti-PARK2 antibodies. Immunoprecipitated proteins were detected by Western blot. Sixty micrograms of HeLa cell lysates were
loaded as an input control.
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lyze their structure using CD spectrometer (Fig.6). The estimated sec-
ondary structural content at pH 7 were 7% α-helix, 53% β-sheet, 19%
β-turn and 17% random coil for PARK2 and 5% α-helix, 34% β-sheet,
19% β-turn and 42% random coil for PARK2ΔC40, respectively. The
NRMSD for secondary structure analysis is 0.131. Obviously, the trun-
cation of the 40 amino acids at the C-terminus of PARK2 causes an in-
crease of random coil from 17% in wild-typed to 42% in PARK2ΔC40
and a decrease of β-sheet from 53% in wild-typed PARK2 to 34% in
PARK2ΔC40. The structural change may explain the cause of altered
biochemical property for PARK2ΔC40.Fig. 6. Circular dichroism spectra of PARK2 WT (■) and PARK2ΔC40 (Δ) respectively.
The concentration for both PARK2 WT and PARK2ΔC40 used in measurements was
50 μM. It can be seen that PARK2 WT mainly adopts a β-sheet conformation while
PARK2ΔC40 adopts mainly a random coil structure.4. Discussion
Previously, PARK2 had been found to interact with γ-tubulin and
to be recruited to centrosomes in response to the inhibition of protea-
somal function during interphase [9]. In the present study, our results
demonstrate that PARK2 is also a centrosome-associated protein in
mitosis. Moreover, unlike proteins such as securin, the protein level
of PARK2 does not ﬂuctuate during the cell cycle.
In the eukaryotic cell, the spindle assembly checkpoint supervises
the integrity of mitotic spindles and the attachment of paired sister-
chromatids to the spindle, thereby ensuring precise separation of
paired sister-chromatids into two daughter cells after mitosis. The
SAC prevents chromosome mis-segregation and aneuploidy which
are thought to be highly associated with tumorigenesis. Although
the role of the centrosome in the SAC is still unclear, recent evidence
has revealed that the centrosomal proteins are also required for acti-
vation of the SAC [12,13]. Here, our results demonstrate that PARK2
truncations also impairs the activation of the SAC: ectopic expression
of PARK2ΔC40, but not wild type PARK2, induced formation of mutli-
nucleated cells in the presence of nocodazole, bypassing the mitotic
arrest. This is also consistent with recent observations that PARK2
knockdown results in aberrant mitosis and formation of multinu-
cleated cells [6].
Previous studies have shown that the SAC-related protein, MAD1,
can self-interact and that this self-interaction is required for normal
function in activation of the SAC [24]. Similarly, though PARK2ΔC40
did not alter its localization to the centrosome, PARK2ΔC40 appeared
to lose its self-interaction, and its ectopic expression resulted in a de-
fect in the SAC and an accumulation of multinucleated cells, suggest-
ing that PARK2ΔC40 may serve as a dominant negative role in SAC
activation.
Based on our present results, we cannot exclude the possibility
that PARK2 has an indirect role in the SAC via transcriptional regula-
tion because the RING2 domain of PARK2 is a putative transcriptional
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regarded as a transcriptional repressor for p53 expression by direct
binding to a p53 regulatory sequence [29]. Thus, it is possible that
PARK2 may positively regulate proper expression of the SAC pro-
tein(s) at the transcriptional level, as it has been shown that a loss
of transcriptional activity results in a decrease in expression of the
SAC protein(s), inactivating SAC [30].
Loss of dopaminergic neuronal cells is a common phenomenon in
Parkinson's disease. PARK2 protects dopaminergic neurons from apo-
ptosis in the presence of microtubule-depolymerizing PD toxins such
as rotenone or colchicine [31]. Our results demonstrate that ectopic
expression of PARK2ΔC40 results in severe lethality even without
nocodazole. It is possible that expression of PARK2ΔC40 causes failure
to correct misaligned chromosomes and premature progress into
anaphase, which may result in chromosome loss in daughter cells,
leading to cell death.
In colorectal carcinoma, tumorigenesis is a process with multi-
step changes, and APC mutation and chromosome instability are the
key events in this process [32,33]. Interestingly, heterozygous
PARK2 deletion accelerates intestinal adenoma development in APC-
Min mutant mice [34]. Combined with our results, this raises the pos-
sibility that PARK2 truncations promote carcinogenesis by impairing
SAC and thus increase the probability of chromosome instability. In
addition, PARK2 is thought to be a tumor suppressor due to that
loss of PARK2 expression was reported in non-small cell lung, ovarian
hepatocellular and breast cancers [35–38]. Though mutations in
PARK2 were found in a small subset of patients with parkinsonism
[39], previous study with large cohort showed increased risk of mel-
anoma, nonmelanoma skin cancer and breast cancer in PD patients
[40]. It is worth to further investigate the correlation between cancer
and PD patients with PARK2 mutation or deletion.
In conclusion, our present study demonstrates that PARK2 can lo-
calize to the centrosomes during mitosis and alternation of PARK2
structure may impair SAC function in prometaphase. Furthermore,
C-terminus deletion of PARK2 led to a loss of self-interaction and
resulted in a higher frequency of multinucleated cells. The SAC defect
is highly associated with tumorigenesis and causes uneven chromo-
some separation, which may also shed another light to explain the
cause of neuron cell death in PD.
Supplementary materials related to this article can be found on-
line at doi: 10.1016/j.bbadis.2011.12.007.
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